AnCan thanks the following sponsors for making this recording possible: Novartis, Blue Earth Diagnostics and Foundation Medicine.
Views expressed in this Recording are solely the opinion of AnCan Foundation, our Moderators and Participants.
AnCan does not accept sponsored promotion. Any drugs, protocols or devices discussed are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/
Join our other free and drop in groups:
Men (Only) Speaking Freely…1st & 3rd Thursdays @ 8.00 pm Eastern https://ancan.org/men-speaking-freely/
Veterans Healthcare Navigation… 1st & 3rd Tuesdays @ 8.00 pm Eastern Schmier Room https://ancan.org/veterans/
Veterans Speaking freely… 4th Tuesday @ @ 8.00 pm Eastern Schmier Room
Editor’s Pick: Two (2) younger Newbies both need better QBs… AND we have another hydrocele
Topics Discussed
Agent Orange Newbie doing well on RT and doublet; younger Newbie with possible variant PrCa needs solid GU med onc; 2nd younger Newbie also needs to upgrade his MO – is he stuck in doublet?; scans suggest Jevtana not holding disease – pasritamig trial next?; debulking to start with IMRT; does coffee creamer interfere with treatment?; hydrocele not the first time for AnCan; nocturia and RT proctitis cause problems; Orgovyx coming soon; Dr. E in his future
John, thank you for the recommendation! And yes, I can get to UofC easily! I just retired…..lots of free time!
Don Rogers sent: 4:08 PM
Hi John, Nice to hear you are doing well. Everything here in Boca Raton is also wonderful. I am doing great, PSA still undetectible. Looking forward to going on a Disney Cruise with the entire family in early July. Mary and I then go on a 10 day camping trip to Yellowstone. Let me what you find out at your 3 month visit with your oncologist. My best always, Don
Len Sierra sent: 4:21 PM
EZH2 inhibitors: Mevrometostat (PF-06821497): An investigational selective inhibitor of enhancer of zeste homolog 2 (EZH2) being studied in combination with XTANDI for mCRPC. Several Phase 3 trials (MEVPRO-1 and MEVPRO-2) are ongoing.
Bob McHugh sent: 4:49 PM
Lomotil or Immodium?
Jim Ekrut, Ft. Worth, TX sent: 4:51 PM
Imodium doesn’t seem to help much. I’m hoping the gastroenterologist will prescribe Lomotil, but he initially hesitated because it’s a controlled substance.
Jim Marshall, Vet Sup Grp. Moderator sent: 4:56 PM
The LATITUDE Trial, 2017, had HS Abi + 10mg. and a few years later HS dropped to 5mg although CR stayed at 10mg. Jim M
Jim Ekrut, Ft. Worth, TX sent: 5:04 PM
Thanks so much for a helpful session! Until next time.
AnCan thanks the following sponsors for making this recording possible: Novartis, Blue Earth Diagnostics and Foundation Medicine.
Views expressed in this Recording are solely the opinion of AnCan Foundation, our Moderators and Participants.
AnCan does not accept sponsored promotion. Any drugs, protocols or devices discussed are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/
Join our other free and drop in groups:
Men (Only) Speaking Freely…1st & 3rd Thursdays @ 8.00 pm Eastern https://ancan.org/men-speaking-freely/
Veterans Healthcare Navigation… 1st & 3rd Tuesdays @ 8.00 pm Eastern Schmier Room https://ancan.org/veterans/
Veterans Speaking freely… 4th Tuesday @ @ 8.00 pm Eastern Schmier Room
Editor’s Pick: No Newbies – but repeating topics: incontinence; heart issues; and, intermittent vs continuous hormone therapy
Topics Discussed
Foamy gland AnCan’r does well with Pluvicto but has urinary issues; incontinence issues defer salvage RT; PCPEP program solid but time consuming; AnCan’r getting AUS this week; neck fan outperforms venlafaxine for hot sweats; low T and still hot sweats; Gent on abi cuts back his prednisone and has muscle pains; are cardio issue down to oncology treatments/; after 24 mo doublet, is it time for a change?; Dr. E’s available to sort his protocol – our AnCan’r just has to call; ending HT takes time to reverse the side effects
SDHA sig for paragangliomas (noncancerous) and GI stromal tumors, and pheos. We need not be concerned it looks like
Len Sierra sent: 6:18 PM
From the AnCan website, my comments from 2024: Tumor responses improved following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264443/ Conclusions: Durable PSA responses occur in up to 40% of patients following a ‘steroid switch’ for PSA progression on abiraterone and prednisone
AnCan thanks the following sponsors for making this recording possible: Novartis, Blue Earth Diagnostics and Foundation Medicine.
Views expressed in this Recording are solely the opinion of AnCan Foundation, our Moderators and Participants.
AnCan does not accept sponsored promotion. Any drugs, protocols or devices discussed are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/
Join our other free and drop in groups:
Men (Only) Speaking Freely…1st & 3rd Thursdays @ 8.00 pm Eastern https://ancan.org/men-speaking-freely/
Veterans Healthcare Navigation… 1st & 3rd Tuesdays @ 8.00 pm Eastern Schmier Room https://ancan.org/veterans/
Veterans Speaking freely… 4th Tuesday @ @ 8.00 pm Eastern Schmier Room
Editor’s Pick: LDR recurrence requires HDR follow-up. Low meeting demand leads to many open-mic Qs.
Topics Discussed
Focal HIFU therapy recurs as 3+3 in gland – which group to attend?; our military chaplain is stable but needs VA help; Frank very happy with AnCan’s GU med onc match; treating LDR brachy recurrence with HDR and SBRT; seeking next line of systemic treatment that’s not chemo or PSMA driven; spot RT for skull Mx; low tech swamp cooler hangs around the neck; old ivermectin/fenbendazole chestnut booted; 6x Pluvicto successfully completed; strategy for next chemo session; oxybutynin for hot flashes; E2 patch does not cause leg DVT; germline Gent questions need for counseling
Chat
Bob Schwartz, USN, Venice, FL sent: 3:45 PM
Frank, you help as much as you get help. Don’t ever doubt how much we appreciate you.
AnCan thanks the following sponsors for making this recording possible: Novartis, Blue Earth Diagnostics and Foundation Medicine.
Views expressed in this Recording are solely the opinion of AnCan Foundation, our Moderators and Participants.
AnCan does not accept sponsored promotion. Any drugs, protocols or devices discussed are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/
Join our other free and drop in groups:
Men (Only) Speaking Freely…1st & 3rd Thursdays @ 8.00 pm Eastern https://ancan.org/men-speaking-freely/
Veterans Healthcare Navigation… 1st & 3rd Tuesdays @ 8.00 pm Eastern Schmier Room https://ancan.org/veterans/
Veterans Speaking freely… 4th Tuesday @ @ 8.00 pm Eastern Schmier Room
Editor’s Pick: Many tasty tips this week… our fave – clinical trials DON’T cover all costs
Topics Discussed
Liquid biopsies and biomarkers; Bispecific T-Cell Engagers (BITE) for TP53+RB1 Gent; is it time to test for small cell? – Provider doesn’t think so; dry mouth from denosumab/Xgeva – not quite, that’s ONJ – great dental health discussion; Reel Recovery takes his mind off seeking HT break; germline negative, but should T3b Gent stop HT after 9 months; the 2 Davids discuss trials managing oligoMx lightly; clinical trials often don’t cover all costs; our first Long Game man goes onto mono daro with 6 months NCI grace; Dr. E orders more tests to guide HT treatment – and suggests Good Patch for hot flashes; don’t worry yet about ‘morphing’ tests; PPI can elevate chromogranin; hypersensitivity to docetaxel demands dose adjustment; better GU doc on Florida Gulf Coast
Chat
Larry in AK sent: 5:13 PM
I will seek circulating tumor cell analysis searching for evolutionary changes in my cancer over time. Still in its infancy as a tool
Danny Lankford (Minnesota) sent: 5:29 PM
My wife and I are using Open Evidence. https://www.openevidence.com/ but you need an NPI (provider ID) to access it. It’s been amazing to help me along on my journey.
AnCan – Rick sent: 5:44 PM
oxybutynin -ditropan
Alfredo in Wimberley sent: 5:44 PM
OXYBUTYNIN (ox i BYOO ti nin) treats symptoms of an overactive bladder, such as loss of bladder control or frequent need to urinate. It works by relaxing muscles in the bladder. It belongs to a group of medications called antispasmodics. This medicine may be used for other purposes; ask your health care provider or pharmacist if you have questions. COMMON BRAND NAME(S): Ditropan XL
Danny Lankford (Minnesota) sent: 5:45 PM
same here on the venlafaxine 37.5mg for me and my mouth is dry as can be
I’m taking 2.5 mg of oxybutynin once a day, in the evening when I take my Apalutamide. Still get warm and sweat, but has taken the intense feeling of a hot flash away.
Another good mtg., have to go, see everyone next week.
Jann Nielsen sent: 6:35 PM
Great meeting. Have to go.
Luther sent: 6:43 PM
Good thing I’m seeing her on Wed. then
Frank Ciambra sent: 6:49 PM
I didnt hear a thing larry
Larry in AK sent: 6:51 PM
There are organizations that re-distribute prescription drugs. It is illegal, but some prosecutors shy away from prosecuting humanitarian bending” of the law.
Alfredo in Wimberley sent: 6:51 PM
I have to leave, best regards to one one and all!
Matt sent: 7:01 PM
evening fella! I’ll follow up. Cheers 😉
Bruce Schrimpf sent: 7:03 PM
Thanks for the information about Dr. Stish writing an article! I have had a long day and will call it a night.
Back in mid-2012, the US Preventative Services Task Force first made the following recommendation with an associated DGrade:
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer.
At the time, prostate cancer advocates objected strongly, warning it would result in many more men diagnosed de novo metastatic, and ultimately more disease specific deaths.
Sadly, we have seen this manifested, especially with respect to younger men. AnCan clearly sees the trend along with a lack of support for the particular needs expressed by younger men living with advanced prostate cancer.
——————————————————————————————————–
2nd Thursday of each month at 8 pm Eastern in The Barniskis Room (222-583-973)
